BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxisÂ
On Jan. 16, 2025, Shionogi Inc. has been awarded a $375 million project agreement through the Rapid Response…
Study maps bed bugs’ genomes in unprecedented detail to find out why they won’t die
On Dec. 17, 2024, scientists from Hiroshima University announced they had mapped near-gap-free and near-error-free genomes of a…
Biotechnology | COVID-19 | HIV | Life Science News | Vaccine
WHO added LC16m8 mpox vaccine to Emergency Use Listing
On Nov. 19, 2024, the World Health Organization (WHO) announced it had granted Emergency Use Listing (EUL) to Japan-based…
Recent COVID-19 vaccination tied to lower risk of long COVID
On Nov. 6, 2024, data from the VENUS (Vaccine Effectiveness, Networking, and Universal Safety) study in Japan revealed…
living microbes discovered in 2-billion-year-old rock in South Africa
On Oct. 2, 2024, a team of researchers from the University of Tokyo announced they had discovered living…
Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
On Sept. 13, 2024, CSL Seqirus and sa-mRNA pioneer Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor…
scientist-run Pathoplexus virus database vows to be transparently run and simple to use
On Aug. 29, 2024, a small team of scientists has launched an open-source database for some of the…
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
On Jul. 3, 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab)…
Novavax and Sanofi announced licensing agreement to co-commercialize COVID-19 vaccine and novel COVID-19-influenza combination vaccines
On May 10, 2024, Novavax announced that it had entered into a co-exclusive licensing agreement with Sanofi. The…
Japan first in the world to approve Dupixentï¾® (dupilumab) for chronic spontaneous urticaria
On Feb. 16, 2024, Regeneron and Sanofi announced that the Ministry of Health, Labor and Welfare (MHLW) in…
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…
The CDC opened new East Asia and Pacific Regional Office in Japan
On Feb. 5, 2024, a U.S. Centers for Disease Control and Prevention (CDC) celebrated the opening of the…
CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
Japan’s MHLW approved CSL and Arcturus’s self-amplifying mRNA vaccine approved for COVID in adults
On Nov. 28, 2023, CSL and Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare (MHLW)…
The Pearl Oyster genome was sequenced
On Nov. 10, 2022, researchers from the Okinawa Institute of Science and Technology (OIST), in collaboration with K….
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
Japanese vaccine database Created to assess Vaccine Effectiveness and adverse events
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
Washington University in St. Louis COVID-19 nasal vaccine technology licensed to Ocugen
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
Novavax announced expanded approval of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 in Japan
On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
Moderna to supply Japan with additional 70 million doses of COVID-19 booster vaccine
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
Takeda announced manufacture and provision of 150 million doses of Novavax COVID-19 vaccine candidate to the government of Japan
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…
Japan became first country to approve Ronapreve (casirivimab and imdevimab) for ttreatment of mild to moderate COVID-19
On Jul. 20, 2021, Roche announced that Japanï¾’s Ministry of Health, Labour and Welfare (MHLW) had approved Ronapreveï¾™(casirivimab…
Japan became first country to approve Regeneron antibody cocktail (casirivimab and imdevimab) for treatment of COVID-19
On Jul. 20, 2021, Regeneron announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) had approved Regeneron’s…
Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…
Japan’s Ministry of Health, Labour and Welfare approved Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted…